Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “C-Met Exon 14 Mutation”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07153770
What this trial is testing

Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer

Who this might be right for
NSCLCMET Exon 14 MutationMET Activating Mutation
Shanghai Pulmonary Hospital, Shanghai, China 34
Testing effectiveness (Phase 2)Looking for participantsNCT04270591
What this trial is testing

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Who this might be right for
C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd. 183
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)WithdrawnNCT03240393
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
CarcinomaNon-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Early research (Phase 1)Active Not RecruitingNCT03993873
What this trial is testing

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorsMET Gene Alterations
Turning Point Therapeutics, Inc. 95
Large-scale testing (Phase 3)Looking for participantsNCT05989542
What this trial is testing

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

Who this might be right for
Non-small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company 136
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06054191
What this trial is testing

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

Who this might be right for
NSCLCBRAF V600 MutationMET Exon 14 Mutation
Sun Yat-sen University 40
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Not applicableLooking for participantsNCT05703516
What this trial is testing

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Who this might be right for
Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals 44
Testing effectiveness (Phase 2)UnknownNCT04647838
What this trial is testing

Tepotinib in Solid Tumors Harboring MET Alterations

Who this might be right for
Solid TumorMET Exon 14 Skipping MutationMET Amplification
Chungbuk National University Hospital 100
Testing effectiveness (Phase 2)UnknownNCT02499614
What this trial is testing

Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Fondazione Ricerca Traslazionale 80
Large-scale testing (Phase 3)Looking for participantsNCT06908993
What this trial is testing

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Who this might be right for
Advanced Non Small Cell Lung CancerMET Exon 14 Mutation
Intergroupe Francophone de Cancerologie Thoracique 133
Early research (Phase 1)Study completedNCT00585195
What this trial is testing

Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Who this might be right for
Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more
Pfizer 596